Do neuraminidase inhibitors prevent influenza?
Husereau D R
Record ID 32002000302
English, French
Authors' objectives:
To summarise the available evidence on two neuraminidase inhibitors (zanamivir and oseltamivir) for the prevention of influenza.
Authors' recommendations:
- Two neuraminidase inhibitors, zanamivir and oseltamivir, are well-tolerated and reduce the likelihood of contracting influenza in both healthy individuals and those who are at risk for developing complications.
- There is insufficient evidence to conclude that neuraminidase inhibitors reduce complications, hospitalization and death from laboratory-confirmed illness.
- Differences between amantadine, zanamivir and oseltamivir exist but the relative contributions of these differences to their overall effectiveness are difficult to assess due to a lack of comparative trials.
Authors' methods:
Overview
Details
Project Status:
Completed
URL for project:
https://www.ccohta.ca/research/index.html
Year Published:
2001
URL for published report:
n/a
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Costs and Cost Analysis
- Antiviral Agents
- Influenza, Human
- Neuraminidase
- Oseltamivir
- Zanamivir
Contact
Organisation Name:
Canadian Coordinating Office for Health Technology Assessment
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Coordinating Office for Health Technology Assessment(CCOHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.